Cytomel Shortage: What Providers and Prescribers Need to Know in 2026

Cytomel Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Cytomel (Liothyronine Sodium) prescriptions, they're reflecting a real and ongoing supply challenge. This briefing is designed to give prescribers a concise, evidence-based overview of the current Liothyronine availability landscape, prescribing implications, and practical resources for ensuring patient continuity of care.

Provider Briefing: The Current State of Liothyronine Supply

Cytomel and generic Liothyronine Sodium have experienced intermittent supply disruptions since approximately 2018. While Liothyronine is not always carried on the FDA's formal drug shortage list, real-world availability at the pharmacy level has been inconsistent — particularly for certain tablet strengths and in high-demand markets.

The situation is best characterized as a chronic supply-demand imbalance rather than an acute shortage event. Availability varies by:

• Geographic region
• Pharmacy type (chain vs. independent)
• Tablet strength (5 mcg, 25 mcg, 50 mcg)
• Generic manufacturer

Timeline of Thyroid Medication Supply Issues

Understanding the broader context helps explain the current Liothyronine situation:

• 2018: Levothyroxine shortages emerge, attributed to manufacturing consolidation and increased demand
• 2020: NP Thyroid recall due to superpotency issues reduces desiccated thyroid supply
• 2021: Nature-Throid and WP Thyroid supply disruptions further strain the NDT market
• 2023-2025: Significant Levothyroxine supply tightening (particularly Mylan/Viatris products) drives increased prescribing of Liothyronine and desiccated thyroid as alternatives or adjuncts
• 2025: Pharmaceutical tariffs on imported APIs introduce cost pressures and potential manufacturing delays
• 2026: Liothyronine availability remains variable; brand-name Cytomel is particularly difficult to source at some pharmacies

Prescribing Implications

The supply challenges create several clinical considerations for prescribers:

Therapeutic Substitution Decisions

When a patient cannot fill their Liothyronine prescription, providers must weigh several factors:

• Clinical indication: Is the patient on T3 monotherapy, combination T4/T3 therapy, or T3 for TSH suppression in thyroid cancer?
• Conversion history: Patients prescribed T3 due to poor T4-to-T3 conversion may not do well with a simple switch to Levothyroxine
• Patient preference and symptom response: Some patients have a strong clinical response to T3 that isn't replicated with T4 alone

Strength and Formulation Flexibility

Consider prescribing flexibility when possible:

• If 25 mcg tablets are unavailable, five 5 mcg tablets may be available (or vice versa)
• Specify "may substitute generic" on prescriptions to broaden pharmacy options
• Consider compounded Liothyronine (including sustained-release formulations) when commercial products are unavailable

Prior Authorization and Formulary Awareness

Brand-name Cytomel frequently requires prior authorization. Many formularies prefer generic Liothyronine, which may be more readily available. When switching patients between brand and generic, monitor thyroid function given potential bioequivalence variability.

Current Availability Picture

Based on pharmacy and patient reports:

• Generic Liothyronine 5 mcg: Generally available but may require checking multiple pharmacies
• Generic Liothyronine 25 mcg: Most commonly prescribed strength; intermittently backordered
• Generic Liothyronine 50 mcg: Less commonly stocked; more prone to unavailability
• Brand-name Cytomel (all strengths): Most difficult to source; many pharmacies no longer routinely stock it

Providers can direct patients to Medfinder for Providers to help locate pharmacies with current Liothyronine stock in their area.

Cost and Access Considerations

Medication cost affects adherence, and Liothyronine costs have been notable:

• Brand-name Cytomel: $80-$300+ per month (cash price)
• Generic Liothyronine: $80-$100 retail; $24-$30 with discount programs (GoodRx, SingleCare)
• Compounded Liothyronine: $30-$90 per month (varies by pharmacy and formulation)
• Insurance: Generic Liothyronine is typically covered with $5-$30 copays; brand-name Cytomel often requires PA

For patients experiencing cost barriers, Pfizer offers the Pfizer RxPathways program, which includes co-pay cards for commercially insured patients and patient assistance for uninsured/underinsured individuals. Additional resources include NeedyMeds and RxAssist.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that helps clinical teams quickly locate pharmacies stocking specific medications, including Liothyronine. This can save significant time compared to phone-based pharmacy checks and improve the patient experience during supply disruptions.

Alternative Medication Reference

When Liothyronine is unavailable, consider these alternatives based on clinical scenario:

• For T3 replacement: Compounded Liothyronine (immediate or sustained-release)
• For combination T4/T3 therapy: Levothyroxine + compounded T3, or desiccated thyroid (Armour Thyroid, NP Thyroid)
• For patients on T3 monotherapy who can tolerate T4: Trial of optimized Levothyroxine with close monitoring

For patient-facing information on alternatives, you may direct patients to our alternatives to Cytomel guide.

Patient Education Resources

Consider sharing these resources with affected patients:

• How to Find Cytomel in Stock Near You
• How to Save Money on Cytomel
• Cytomel Shortage Update for Patients

Looking Ahead

The structural factors driving Liothyronine supply issues — limited manufacturers, rising demand, API sourcing challenges, and tariff pressures — are unlikely to resolve quickly. Practices that build proactive medication access workflows now will be better positioned to support their thyroid patients through continued supply volatility.

Key steps include:

• Building relationships with independent and compounding pharmacies
• Documenting patients' T3 clinical necessity for prior authorization purposes
• Implementing medication access tools like Medfinder in your workflow
• Keeping patients informed about their options so they can act quickly when supply shifts

Final Thoughts

The Cytomel supply situation requires active management from prescribers and clinical teams. By understanding the supply landscape, maintaining prescribing flexibility, and leveraging tools like Medfinder for Providers, you can help ensure your patients maintain access to the thyroid therapy they need.

For a complementary guide on practical pharmacy-level strategies, see How to Help Your Patients Find Cytomel in Stock.